THE biotechnology industry is finally getting closer to an elusive goal: breaking even.
Despite its reputation for developing lifesaving drugs and providing high-paying jobs, the industry has lost tens of billions of dollars since Genentech, the first genetic engineering company, was founded 30 years ago this Friday.
